Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

Table 5 Multiple linear regression models of magnitude of HbA _1c reduction after combination therapy

	Model 1		Model 2		Model 3
	β	P	β	P	β	P
Drug group (0 = glibenclamide; 1 = acarbose)	−0.113	0.410	−0.192	0.127	−0.183	0.126
Gender (0 = female; 1 = male)	0.206	0.110	-	-	-	-
Age (years)	0.134	0.307	-	-	-	-
Disease duration (years)	−0.132	0.313	-	-	-	-
BMI (kg/m²)	−0.217	0.179	-	-	-	-
HbA_1c (%)	0.730	<0.001*	0.718	<0.001*	0.698	<0.001*
MISI	−0.204	0.391	−0.273	0.234	-	-
HOMA-IR	0.384	0.080	0.265	0.148	0.308	0.085
HOMA-β (%)	0.037	0.864	−0.036	0.835	-	-
Insulinogenic index₃₀ (pmol/mmol)	0.091	0.734	-	-	-	-
AUC_ins₁₂₀/AUC_{glu 120}^§(pmol/mmol)	−0.379	0.258	−0.380	0.150	−0.199	0.249
DI₁₂₀	1.009	0.045*	0.936	0.031*	0.696	0.030*
DI₃₀	−0.574	0.226	−0.414	0.176	−0.358	0.142

Multiple linear regression models with HbA_1c reduction after combination therapy as the dependent variable. All independent variables were collected before randomization of the second-line OADs.
*P < 0.005; § total area under curve of insulin within 120 minutes divided by total area under curve of glucose within 120 minutes.
DI, disposition index; HOMA-β, homeostasis model assessment β-cell function; HOMA-IR, homeostasis model assessment insulin resistance index;
Incremental AUC, incremental area under curve during liquid mixed meal tolerance test; MISI, Matsuda insulin sensitivity index.

ISSN: 1758-5996